$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• In 2024, innovative APIs dominated the market, driven by the increasing number of regulatory approvals for new and advanced drugs

  80% confidence

• India and China are emerging as global hubs owing to their large-scale production capacity, skilled workforce, and favorable regulatory initiatives

  80% confidence

• Type 2 diabetes and obesity care have been reshaped by a new class of peptide-based drugs, most notably Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide

  80% confidence

• Pharmaceutical and biotechnology companies still dominate the end-user segment by retaining in-house manufacturing for high-value blockbuster drugs and biologics

  80% confidence

• The global active pharmaceutical ingredients market is projected to reach USD 198.39 billion by 2030 from an estimated USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030

  80% confidence

• Innovative APIs, being protected by patents, are typically priced higher than generic APIs, contributing to their larger market share

  80% confidence

• The pharmaceutical industry has seen increasing manufacturing outsourcing to CMOs in the last 5 years, especially for developing and manufacturing drugs & biologics, such as high-potency drugs, ADCs, among others

  80% confidence

• The expansion of the active pharmaceutical ingredients market has been predominantly fueled by the expanding oncology & rare disease and diabetes product pipeline

  80% confidence

• The pharmaceutical & biotechnology industry segment accounted for the largest share by end user in 2024

  80% confidence

• The Asia Pacific region is projected to grow at the highest CAGR during the forecast period

  80% confidence